About Exelixis, Inc
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
Exelixis, Inc News and around…
Latest news about Exelixis, Inc (EXEL) common stock and company :
Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.
Gainers NeuroMetrix (NASDAQ:NURO) stock increased by 37.8% to $4.3 during Thursday's regular session. As of 13:30 ...
This biotech stock has been on fire since the beginning of the year.
With thrilling long-term prospects, these three are excellent buys.
With its stock down 11% over the past month, it is easy to disregard Exelixis (NASDAQ:EXEL). But if you pay close...
EXEL earnings call for the period ending March 31, 2022.
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about ...
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
In trading on Monday, shares of Exelixis Inc (EXEL) crossed below their 200 day moving average of $19.64, changing hands as low as $19.21 per share. Exelixis Inc shares are currently trading off about 10% on the day..
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:
A small investment can go a long way.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy. This approval allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union, Norway, Liechtenstein and Iceland.
TheEuropean Commission (EC) has approvedIpsen SA's(OTC: IPSEY) Cabometyx (cabozantinib) as monotherapy in ...
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Exelixis Inc (EXEL) was identified as having a larger market cap than the smaller end of the S&P 500, for example DXC Technology Co (DXC), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom. “We are
Stock Market Bounces, But Be Wary; Watch Exelixis, World Wrestling Entertainment, Marriott
Exelixis is the IBD Stock Of The Day as it adds onto a lengthy consolidation ahead of a key test for its headliner cancer treatment.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. The post 7 Top-Rated Biotech Stocks to Buy for Q2 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
The company selected the Philadelphia area over Boston and expects to hire several hundred employees locally.